Australian Ethical Investment was hit in 2022, but cushioned the blow

Nick Sundich Nick Sundich, December 15, 2022

Australian Ethical Investment (ASX: AEF) just issued earnings guidance for the half year ending 31 December 2022. As a fund manager, particularly one with exposure to the tech sector, it was hit by the dour market conditions. But it was able to soften the blow and still anticipates an underlying profit.

 

No time to do stock research, but you still want to invest?
 
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!

 

GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY

 

 

Australian Ethical saved from a FUM decline

In 1HY22 (the 6 months to 31  December 2021), Australian Ethical made an underlying (and net) profit of $5.4m and has $6.9bn in Funds Under Management (up 38%).

This morning it told shareholders it anticipated a similar result this time around – a $4.5m-$5m underlying profit. And FUM actually rose to $8.6bn.

The catalyst was the acquisition of Christian Super and its members into the Australian Ethical platform, contributing $1.9bn. It had a wafer-thin net inflow of $0.12bn, but would have seen a decline in FUM to $6.2bn if not for this deal. 

 

Needs to perform in H2

In absence of another M&A deal, Australian Ethical will need improved market conditions to achieve FUM growth. Whether or not it will be achieved is anyone’s guess.

Of course, this is not to say the company is at risk of collapse. It has been around since 1986 and has substantially grown in recent years, even with the Tech Wreck.

In mid-2019, it had just $3.4bn in FUM, barely over a third of what it has now. And as of 30 November 2022, it has over 100,000 super members and over 13,000 managed fund investors. 

 

 

No time to do stock research, but you still want to invest?
 
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!

 

GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY

 

No credit card needed and the trial expires automatically.

 

 

 

Blog Categories

Get Our Top 5 ASX Stocks for FY25

Recent Posts

Trump vs. Jerome Powell

Trump vs. Jerome Powell: What Happens to the Market If Powell Is Fired?

The relationship between President Donald Trump and Federal Reserve Chair Jerome Powell has often been tumultuous, particularly around decisions regarding…

Telix Pharmaceuticals on the Nasdaq

Telix Pharmaceuticals (ASX:TLX): It’s made ~A$1.7bn in revenue from Illucix, but here’s why the best is yet to come!

What would you have thought if you were told 5 years ago you would see Telix Pharmaceuticals as a successful…

anti woke ETFs

Anti Woke ETFs: Do they practice what they preach and have they outperformed since Trump’s return to power?

Have you ever heard of so-called ‘Anti Woke ETFs’? If you’re sick of companies that are big on ESG, this…